View More Recent Stories

Oct 17, 2025 08:32AM Truist Securities: 'Is Biotech Back?!'

Oct 9, 2025 06:36AM Palvella Therapeutics (PVLA) PT Raised to $90 at Canaccord Genuity

Oct 2, 2025 08:37AM Palvella Therapeutics (PVLA) PT Raised to $80 at Truist Securities

Sep 26, 2025 06:45AM Palvella Therapeutics (PVLA) PT Raised to $95 at H.C. Wainwright

Sep 25, 2025 03:12AM Palvella Therapeutics (PVLA) PT Raised to $70 at Jones Trading

Sep 24, 2025 01:17PM Palvella Therapeutics (PVLA) PT Raised to $90 at Oppenheimer

Sep 24, 2025 12:41PM Palvella Therapeutics (PVLA) PT Raised to $80 at Stifel

Sep 24, 2025 06:01AM Palvella expands QTORIN rapamycin development to angiokeratomas

Sep 19, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Sep 17, 2025 07:33AM Palvella announces scientific publication on rapamycin for venous malformations

Sep 9, 2025 06:04AM Oppenheimer Starts Palvella Therapeutics (PVLA) at Outperform, PT $85

Sep 3, 2025 07:31AM Palvella appoints David Osborne as chief innovation officer

Aug 19, 2025 06:18AM Palvella Therapeutics (PVLA) PT Raised to $66 at Canaccord Genuity

Aug 18, 2025 06:48AM Palvella Therapeutics (PVLA) PT Raised to $75 at H.C. Wainwright

Aug 5, 2025 04:07PM Raymond James Starts Palvella Therapeutics (PVLA) at Outperform

Jul 21, 2025 07:32AM Truist Securities Starts Palvella Therapeutics (PVLA) at Buy

Jun 9, 2025 07:30AM Palvella Therapeutics (PVLA) Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN

May 27, 2025 08:05AM Palvella Therapeutics (PVLA) Appoints Ashley Kline as Chief Commercial Officer

Apr 22, 2025 07:30AM Palvella Therapeutics (PVLA) Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Apr 9, 2025 06:13AM Chardan Capital Markets Starts Palvella Therapeutics (PVLA) at Buy

Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald

Mar 31, 2025 11:32AM Stifel Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Mar 25, 2025 04:07PM Stifel Starts Palvella Therapeutics (PVLA) at Buy

Mar 24, 2025 04:12PM Jones Trading Starts Palvella Therapeutics (PVLA) at Buy

Mar 18, 2025 06:42AM Lucid Capital Markets Starts Palvella Therapeutics (PVLA) at Buy, PT $49

Mar 7, 2025 07:11AM Scotiabank Starts Palvella Therapeutics (PVLA) at Sector Outperform

Feb 11, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Feb 5, 2025 05:29AM TD Cowen Starts Palvella Therapeutics (PVLA) at Buy

Jan 10, 2025 08:05AM Palvella Therapeutics (PVLA) Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations in the Jour

Jan 3, 2025 06:07AM H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Dec 31, 2024 06:12AM Palvella Therapeutics (PVLA) Files for 5.63M Share Offering by Selling Stockholders

Dec 26, 2024 06:29AM H.C. Wainwright Starts Palvella Therapeutics (PVLA) at Buy

View More Recent Stories